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Considerable experimental evidence indicates that the p53
tumour-suppressor gene is involved in hepatocellular carcinoma
(HCC), with a variable incidence according to the geographical
origin of the patients. Mutation of the p53gene and cellular accu-
mulation (nuclear and/or cytoplasmic) of the mutated or wild-type
p53 protein have been considered as factors of poor prognosis in
different types of cancer (for reviews see Soussi et al, 1994;
Zusman, 1995). Investigation of cellular p53 accumulation by
immunohistochemical methods, and sequence analysis of the p53
gene, require tumorous tissue obtained by fine needle biopsy or
examination of the surgical piece, which is a limiting step.
More recently, serum antibodies reacting with the p53 protein
have been detected in cancer patients with a variety of neoplasms
(Schlichtholz et al, 1992; Angelopoulou et al, 1994, 1996;
Volkmann et al, 1993; Houbiers et al, 1995; Lubin et al, 1995a, b;
Bourhis et al, 1996; Coomber et al, 1996; Gadducci et al, 1996;
Ryder et al, 1996; Wild et al, 1995). A prerequisite for a B-cell
response seems to be the accumulation in the tumour of a mutant
or, less frequently, a wild-type p53 protein. Anti-p53 serum anti-
bodies have been associated with poor prognosis and advanced
stage in breast (Schlichtholz et al, 1992; Angelopoulou et al,
1996), head and neck (Bourhis et al, 1996), colorectal (Houbiers et
al, 1995; Coomber et al, 1996) and ovarian (Angelopoulou et al,
1996; Gadducci et al, 1996) cancers. However, serological assess-
ment of anti-p53 antibodies seems also to allow detection of
tumours at an early and therefore more treatable stage (Lubin et al,
1995b; Trivers et al, 1995, 1996). Moreover, this non-invasive test
is adapted to the follow-up of cancer patients in clinical routine
laboratories.
Two previous studies have reported an incidence of 2% and
25%, respectively, for the presence of anti-p53 serum antibodies in
Western populations of HCC patients (Angelopoulou et al, 1994;
Volkmann et al, 1993). In these studies, the presence of circulating
anti-p53 antibodies appeared to be independent of alpha-fetopro-
tein (AFP) levels, a currently used but poorly reliable marker and
predictor of HCC. More recently, another study from a Japanese
group showed an incidence of 32% of positive samples and an
association with a poor prognosis (Shiota et al, 1997). No informa-
tion was available about the follow-up of the patients.
Three years ago, we initiated a prospective study to determine
the interest of including the assessment of anti-p53 antibodies in
the follow-up of HCC patients. We also investigated whether it
correlated with clinicopathological variables and patient survival.
p53 immunohistochemistry was performed when the tumours
were resected and nucleotide sequence of the entire coding region
of the p53gene was determined in patients exhibiting anti-p53
serum antibodies.
We report here the results of this study on 130 consecutive
European HCC patients tested for the presence of anti-p53 serum
antibodies before treatment and periodically during the clinical
course of the disease for a mean period of 30 months.
PATIENTS AND METHODS
Study population
Anti-p53 serum antibodies detection was performed on 130
consecutive outpatients with confirmed HCC (30 women, 100
men, mean age 54.8 years, range 18—85) between October 1994
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and December 1995. All the patients were assessed before treat-
ment and 2—10 times during the course of the disease. All the
assays were performed in duplicate.
Diagnosis of HCC was made by ultrasonography and computer-
ized tomography and serum AFP, and confirmed, upon resection,
by histological examination of the surgical piece. Size (maximal
diameter of the tumour), number of nodules and total volume of the
tumour were calculated using imaging and volumetric scanning
techniques, including intraoperative ultrasound. The number and
size of nodules, the grade according to Edmonson￿s classification,
the presence of portal or hepatic vein invasion and the infiltration of
the fibrous capsule were reported by the pathologist. During the
follow-up of the patients, abdominal ultrasound and thoracic and
abdominal volumetric scanning were periodically performed. Bone
scintigraphy was prescribed when there was bone pain.
In 105 out of 130 patients, HCC had developed on a cirrhotic
liver, 20 out of 130 had chronic hepatitis; in five patients, HCC had
developed on a normal liver and no known hepatotropic viruses
were found. HCC was of viral origin in 81 patients, and consequent
upon excessive alcohol consumption in 16 patients. In 28 patients,
viral and alcoholic aetiological factors were associated.
Seventy-eight patients had undergone liver surgery (49 partial
hepatectomy and 29 total hepatectomy followed by orthotopic
liver transplantation). One to three treatments by arterial
chemoembolization using doxorubicin according to a protocol
reported previously by us (Bismuth et al, 1992), were performed in
105 patients. All the patients were tested for presence of circu-
lating anti-p53 antibodies at least once before beginning
chemotherapy.
We also tested two control groups, including the sera from 40
healthy subjects and from 36 patients with cirrhosis. In the latter
group, there were 30 men and six women (mean age 47 years). The
diagnosis of cirrhosis was made on the basis of liver biopsy
histology. HCC was excluded in the latter patients by abdominal
ultrasonography, CT scan, and AFP measurement.
Detection of serum anti-p53 antibodies
The detection of anti-p53 antibodies in patient sera was performed
with a commercially available enzyme-linked immunosorbent assay
(Anti-p53 ELISA, Pharmacell Paris, distributed by Immunotech,
Marseille, France). The assay was based on an indirect technique
using microtitre plates coated with recombinant wild-type human
p53 protein or with a control well coated with the neutral antigen.
This assay was performed according to the manufacturer￿s instruc-
tions with the following specifications: 1/100 diluted patient serum
was added for 60 min at 20—25°C, with shaking, to microtitre wells
coated with recombinant wild-type human p53 protein (to detect
specific anti-p53 antibodies), or with a control protein (to detect non-
specific interactions). After washing, goat anti-human IgG antibody
conjugated with peroxidase was added for 60 min at 20—25°C with
shaking. Finally, the substrate 3,3¢,5,5¢-tetramethylbenzidine (TMB)
was added for 10 min. The enzymatic process was stopped by adding
2 N sulphuric acid. Light absorption was measured at 450 nm on a
spectrophotometer (Dynatec, Paris, France). In this assay, non-
specific background of each sample corresponded to the absorbance
measured on wells coated with control protein.
Anti-p53 antibodies were considered positive in a sample for an
index value [specific signal of the sample (p53 net absorbance
—control protein net absorbance) /specific signal of the lower
positive manufacturer￿s control serum] ‡ 1.1. Positive sera were
checked at least twice in two independent experiments and the
follow-up of a patient positive for anti-p53 antibodies was
performed on the same plate.
Specificity of anti-p53 antibodies detection and
purification of recombinant human p53
The validity of this test was established by the lack of anti-p53
antibodies detection in 200 sera from patients without malignan-
cies (Lubin et al, 1995a), and in positive serum (dilution 1/100) of
this study incubated for 30 min at 37°C with a range of concentra-
tions of purified p53 protein (0.1—1 ng ml—1) before titration. The
purification of the p53 protein was performed according to the
procedure that follows. The recombinant baculovirus used was
vEV 55 p53 (O￿Reilly and Miller, 1988), generously provided by
Dr J Baudier. Nuclear extract of baculovirus-infected SF9 cells
was first purified on a Q sepharose fast-flow column (Pharmacia,
Uppsala, Sweden) as described previously (Delphin et al, 1994),
then immunoaffinity purified on Protein A Sepharose Matrix
covalently coupled to the monoclonal antibody Pab 122. Elution of
p53 was carried out using a synthetic peptide comprising the Pab
122 epitope (amino acids 370—378). Eluted p53 was shown to be
95% pure on acrylamide gel (Lechner and Laimins, 1994) and
stored in liquid nitrogen after extensive dialysis against 50% glyc-
erol, 20 mM dithiothreitol and 1 mM Pefabloc [4-(2aminoethyl)-
benzenesulphonylfluoride hydrochloride; Boerhinger, Mannheim,
Germany] containing buffer.
Immunohistochemical detection of p53 protein
Tissue sections were dewaxed in xylene, followed by graded
alcohol, then rehydrated, microwaved in 0.01 M citrate buffer,
pH 6.0, and blocked with normal horse serum. The monoclonal
antibody Pab 1801 (Dako, Glostrup, Denmark), which recognizes
a denaturation resistant epitope in the N-terminus of the molecule,
was used to detect cellular accumulation of wild-type or mutant
p53. Bound antibody was detected by incubation of the section
with a biotinylated horse anti-(mouse Ig) antibody followed by
streptavidin—horseradish peroxidase complex. Colour was devel-
oped with diaminobenzidine tetrahydrochloride and sections were
counterstained with haemotoxylin before mounting. A negative
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Figure 1 Correlation between the index value of anti-p53 antibodies
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control obtained by the replacement of primary antiserum with
Tris buffer and a positive control (a positive case of human colon
cancer) were included in each series. For each section, the
percentage of tumour cells that stained positive for p53 was deter-
mined. Tumours were considered as positive when more than 20%
of cells stained positively for p53.
Tumour samples and DNA preparation
The tumour samples were dissected from surgical specimens and
did not include any necrotic or non-cancerous liver tissue. They
were then frozen immediately and stored in liquid nitrogen until
use. In one case, tumour samples were obtained from paraffin
sections of the fixed tumour. High molecular weight DNA was
isolated by proteinase K and phenol/chloroform treatments,
washed with 70% ethanol, vacuum dried, resuspended in water
and quantified by optical densitometry and gel analysis.
DNA sequence analysis
Tumour DNA from six of the nine ELISA p53 positive patients
was available for DNA sequencing. Exons 2—11 were amplified in
five independent polymerase chain reaction (PCR) amplifications,
as previously reported by us (Bourdon et al, 1995), with one non-
biotinylated primer and the other one biotinylated at the 5¢ end.
This allowed further purification of the PCR products on strepta-
vidin-coated magnetic beads (Dynabeads M-280, streptavidin,
Dynal, Oslo, Norway).
Sequencing was performed on both strands using dye terminator
chemistry and ABI prism 310 automated DNA sequencer according
to the manufacturer￿s recommendations (Perkin Elmer, Applied
Biosystems, Courtaboeuf, France). Sequencing primers were as
follows: exons 2—4, Ui1, Ui3, Li3A, Li4b; exons 5 and 6, Ui4B, Ui5,
Li5, Li6B; exons 7—9, Ui6B, Ui7, Li7, Li9; exon 10, Ui9, Li10A;
exon 11, Ui10, Li11 (Bourdon et al, 1995). Mutations were
confirmed at least twice on independent PCR amplification products.
Statistical analysis
Statistical analysis was carried out with the SAS software system
(SAS Institute, Cary, NO, USA) and differences were considered
significant when the probability values obtained from the statis-
tical test were 0.05 or less. Clinical and biological characteristics
of patients were expressed as means ± s.d. Comparisons were
performed with the c2 Fischer exact test. Survival curves without
recurrent disease were constructed using the actuarial Kaplan—
Meier method. The statistical significance between curves was
analysed by the log-rank test.
RESULTS
Incidence and specificity of p53 serum antibodies in
HCC patients
We tested for anti-p53 serum antibodies in a series of 130 consec-
utive outpatients with confirmed HCC; 19 of them presented with
extrahepatic metastases. Of these 130 patients, only nine (7%) had
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Figure 2 Time course of anti-p53 serum antibodies in the nine patients seropositive for anti-p53 antibodies. The shaded area corresponds to the period
preceding partial hepatectomy or orthotopic liver transplantation. Histograms represent the index value of anti-p53 antibodies (positive threshold 1.1). Curves
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circulating anti-p53 antibodies before treatment (chemotherapy
and/or surgery); one patient out of the nine positive patients for
anti-p53 antibodies had extrahepatic metastases.
To check the specificity of the anti-p53 antibodies ELISA assay,
we tested two control populations. The 40 healthy subjects assayed
for circulating anti-p53 antibodies tested negative; two patients out
of the 36 cirrhotic patients were found positive. We also incubated
sera from the nine positive patients with increasing concentrations
of purified p53 antigen to check whether the antibodies detected in
the serum were well directed against the p53 protein. The ELISA
was then performed and progressive disappearance of the signal
was observed. Complete extinction of the signal was obtained for a
concentration of 1 ng ml—1 of p53 protein added to each of the nine
serum samples tested (data not shown).
Correlation between detection of circulating anti-p53
antibodies and AFP levels
The presence of anti-p53 antibodies in serum was not correlated
with serum AFP levels. Indeed, of the 130 patients tested, 81 had
serum AFP levels above the normal range (62%), whereas only
nine patients had anti-p53 serum antibodies (Figure 1). However,
it is interesting to note that, before surgery, one patient out of the
nine positive patients for anti-p53 serum antibodies (patient 8 in
Figure 2) had AFP levels in the normal range. In the post-operative
period, AFP levels decreased to normal for eight of these nine
patients, although seven of them still tested positive for anti-p53
serum antibodies.
Biological course of the nine patients positive for anti-
p53 serum antibodies
Several serum samples were obtained at different times during the
course of the disease. All the patients who tested negative at diag-
nosis for anti-p53 circulating antibodies remained negative during
the follow-up, besides variations in AFP levels. The follow-up of
the nine positive patients is shown in Figure 2. Eight of them had
received at least one treatment by arterial chemoembolization
without subsequent disappearance of anti-p53 serum antibodies.
Surgery was not possible for one of them (patient 9), who was
treated by chemoembolization. He had developed lung and bone
metastases associated with a considerable increase of AFP levels
(14 125 to 22 440 ng ml—1) and died during the course of the study.
The other eight patients (patients 1—8) had undergone partial hepa-
tectomy (n = 4) or complete hepatectomy followed by orthotopic
liver transplantation (n = 4). They all tested positive for anti-p53
serum antibodies before surgery, with index values varying from
1.1 to 31.0. After surgery, only one patient (patient 1) showed
complete disappearance of these antibodies within a period of 2
months. This patient had undergone major hepatectomy for a volu-
minous HCC (20 cm) with a surgical margin close to the tumour
limits. Thirty-four months later, no circulating anti-p53 antibodies
were detected and no recurrent disease was diagnosed.
Patients 2—4 showed temporary disappearance of anti-p53
serum antibodies which rose again 1—21 months after surgery,
whereas at the same time serum AFP levels remained normal.
However, patient 2 exhibited a small progressive increase in AFP
levels associated with positivity of anti-p53 serum antibodies. In
May 1998, imaging and volumetric scanning techniques showed
no recurrence of the disease in these three patients 29, 38 and 18
months after surgery respectively.
Patients 5—8 remained positive for circulating anti-p53 anti-
bodies after surgery whereas AFP levels became normal, although
patient 8 had normal AFP levels before surgery. Patients 6 and 7
were lost for follow-up, whereas patients 5 and 8 had no recurrent
disease 36 and 22 months after surgery respectively.
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Figure 3 Survival rate without recurrence in the eight patients positive for
the presence of anti-p53 serum antibodies compared with the 24 patients
who exhibited vascular invasion in their tumour, but no serum anti-p53
antibodies
Table 1 Characteristics of the tumours according to the presence or
absence of serum anti-p53 antibodies in patients who underwent surgery
Anti-p53 Anti-p53
negative positive P-value
(n = 70) (n = 8)
Underlying liver
Cirrhosis 55 5 ns
Chronic hepatitis 4 0 ns
No cirrhosis 11 3 ns
Aetiology
Viral 44 5 ns
Alcoholic 9 2 ns
Viral + alcoholic factors 15 0 ns
No aetiological factor 2 1 ns
Number of nodules
13 3 4 n s
21 9 2 n s
³ 31 8 2 n s
Diameter of nodules
< 3 cm 31 2 ns
³ 3c m 3 9 6 n s
Capsule
Present 18 4 ns
Absent of infiltrated 52 4 ns
Edmonson’s grade
I5 1 n s
II 27 5 ns
III 12 1 ns
IV 8 0 ns
Vascular invasion
Yes 24 7
No 28 1 <0.03
p53 immunohistochemistry
Positive 7 6
Negative 45 1 <0.01608 R Saffroy et al
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Tumour characteristics of the patients positive for
presence of anti-p53 serum antibodies
Of the 130 patients, 78 underwent surgery. All the resected livers
were analysed by the same pathologist who was unaware of the
anti-p53 serum antibodies results. The histological characteristics
of the tumours of patients free of circulating anti-p53 antibodies
(n = 70) were compared with the p53 seropositive patients (eight
out of nine patients, Table 1). The presence of anti-p53 antibodies
cannot be explained by differences in the underlying liver disease
(five cirrhosis, three non-cirrhotic tissue), aetiology (two alco-
holic, five viral cirrhosis and one without viral or alcoholic factors)
or number of nodules (four patients had one nodule, two patients
had two nodules, and two patients had more than three nodules).
The diameter of the main nodule varied from 2 to 20 cm. All the
tumours were encapsulated, but in half of them the capsule was
infiltrated. Edmonson￿s classification was analysed when the
tumour was not completely necrosed and showed one type I, five
type II and one type III.
Conversely, considerable incidence of portal or hepatic vein inva-
sion was observed in the group of patients positive for anti-p53 serum
antibodies (seven out of eight patients). This incidence was also
analysed in the group of 70 patients operated for HCC and negative
for anti-p53 antibodies. Only 52 out of 70 tumours were available for
such an analysis because the remaining tumours showed necrosis. Of
these 52 tumours, 24 exhibited vascular invasion. The difference
between the two groups was significant (P < 0.03, c2 Fischer exact
test). We also compared the survival rate without recurrence between
these two groups using the Kaplan—Meier technique. The log-rank
analysis exhibited a significant difference in the duration of survival
without recurrence between the two groups (P = 0.05; Figure 3)
towards longer survival in the group of patients positive for anti-p53
serum antibodies.
Association between the presence of anti-p53 serum
antibodies and expression of p53 in the corresponding
tumour
p53 immunohistochemistry was performed on the tumours of
operated patients when no necrosis was observed. Of the nine
patients who had anti-p53 serum antibodies, seven were investi-
gated. Six out of the seven tumours analysed exhibited an accumu-
lation of p53 protein. Only seven of the 52 tumours from anti-p53
antibody-negative patients exhibited nuclear p53 accumulation
(P<0.01, Table 1).
Sequence analysis of the entire coding region (exons 2—11) of
the p53 gene was performed on tumour DNAs from patients who
had anti-p53 serum antibodies (one tumour was necrosed and one
was not available for DNA preparation). Only one of the six
samples analysed was mutated (exon 6, codon 195, Leu®Phe).
DISCUSSION
We studied 130 consecutive patients with proven hepatocellular
carcinoma and found a humoral response to p53 in nine of them
(7%). Presence of anti-p53 serum antibodies significantly corre-
lated with accumulation of p53 protein in the tumour, and was
associated with vascular invasion. No significant correlation was
found between the presence of anti-p53 serum antibodies and AFP
levels, number and size of nodules, and prognosis. However, a
significant higher survival rate without recurrence was observed in
the group of patients positive for serum anti-p53 antibodies.
The test used in our study and derived from the assay developed
by Lubin et al (1995a) allows great specificity. It has previously
been used for assay on 1000 sera from cancer patients (breast, lung,
colon, pancreas, thyroid, leukaemia), and on 200 sera from patients
without malignancy. We also tested a series of 40 healthy patients;
all gave negative results. In a population of 36 cirrhotic patients,
two (5.5%) tested positive. It is possible that the cirrhotic liver of
these seropositive patients harboured occult HCC-producing anti-
p53 antibodies. Similarly, the presence of circulating anti-p53
serum antibodies has been observed in heavy smokers and bettel
users (Lubin et al, 1995b; Kaur et al, 1997). In our assay, the use of
a control well (serum of the patient without p53 antigen) for each
test erases the non-specific reaction. Therefore, despite a great vari-
ation in the background of the signal from one serum to another,
false-positive results, as could be the case with the serum of
patients suffering from an autoimmune disease, can be avoided. In
addition, the progressive and complete disappearance of the signal
when positive sera are incubated with a range of increased concen-
trations of purified p53 protein proves the specificity of our assay,
but it cannot be ruled out that a certain lack of sensitivity provides
some false-negative results. Indeed, the incidence of 7% found in
this study is higher than the 2% reported by Angelopoulou et al
(1994), and lower than the 25% and 32% reported by Volkmann et
al (1993) and Shiota et al (1997) respectively. These discrepancies
can probably be explained by the different geographical origins of
the tumours and by the nature of the assays used by the different
groups. Angelopoulou et al (1994) used an ELISA with coated anti-
p53 antibodies to avoid denaturation of the p53 protein, and
reported an incidence of 2% for presence of anti-p53 serum anti-
bodies in HCC. Volkmann et al (1993) developed an immunoblot
assay, difficult to use routinely and probably the cause of false-
positive results because of the presence of non-specific bands. This
could account for the high incidence reported in their series. Shiota
et al (1997) used an ELISA developed by Diannova (Munster,
Germany). Recently, this test showed a lack of specificity in head
and neck cancer with a control population exhibiting 24% of posi-
tivity (Wollenberg et al, 1997). The absence of a control well could
explain these false-positive results. These previously reported high
incidences of anti-p53 serum antibodies in liver tumours is different
from what has been reported in other tumour types. Indeed, pres-
ence of anti-p53 serum antibodies is usually indicative of abnormal
p53 protein expression in a high proportion of tumour cells; but the
incidence of circulating anti-p53 antibodies is generally lower than
the incidence of p53 protein accumulation in tumours (Lubin et al,
1995a). For example, in different series of breast and lung carci-
nomas, in which p53 immunohistochemistry analysis showed
20—40% and 60—70% positivity, respectively, the presence of anti-
p53 serum antibodies was reported to be 15% and 30% respectively
(Schlichtholz et al, 1992; Lubin et al, 1995b). In European HCC,
we and others have previously reported p53 protein accumulation
ranging from 31% to 45% (d￿Errico et al, 1994; Volkmann et al,
1993; Bourdon et al, 1995), and p53 gene mutation to be in the
vicinity of 15% (Challen et al, 1992; Kress et al, 1992; Debuire
et al, 1993). Thus, the 7% incidence of anti-p53 serum antibodies
found in our series is in agreement with the level expected.
All the patients were tested before chemotherapy and/or surgery.
There was no association between presence of anti-p53 serum anti-
bodies and patient sex or age, clinical stage and histological type
of the tumour, underlying disease, number and size of nodules or
presence of extrahepatic metastases. These results are in agree-
ment with the findings of Ryder et al (1996) and Volkmann et alMonitoring anti-p53 antibodies in HCC patients 609
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(1993) but show a discrepancy with the results of Shiota et al
(1997), who reported a correlation with the number of nodules. No
correlation was observed with AFP levels, as previously reported
by others (Volkmann et al, 1993; Raedle et al, 1995; Ryder et al,
1996). Indeed, circulating anti-p53 antibodies were detected in one
out of nine patients with normal levels of AFP before surgery and
in seven patients with normal levels of AFP after surgery.
Our data show that presence of circulating anti-p53 antibodies
correlates with p53 protein overexpression in the tumour because
seven out of eight patients positive in ELISA also tested positive
in immunohistochemistry. This relationship between p53 over-
expression in the tumour and presence of anti-p53 serum anti-
bodies has already been reported in different types of malignancies
including HCC (Davidoff et al, 1992; Angelopoulou et al, 1996;
Ryder et al, 1996; Trivers et al, 1996). However, cellular accumu-
lation of the p53 protein does not appear to be the sole contributing
factor. Mutation of specific exons of the p53 gene has also been
incriminated. It has been postulated that the development of an
immune response to a mutant protein may depend on mutant p53
protein complexes with a 70-kDa heat shock protein (HSP70)
(Davidoff et al, 1992). However, this hypothesis has been ques-
tioned (Wild et al, 1995). In the present study, only one tumour out
of six was found mutated, although complete sequencing of the
p53 gene was performed. This low incidence of mutations in the
p53 gene in HCC is in agreement with that which has been
reported in the literature (Challen et al, 1992; Kress et al, 1992;
Debuire et al, 1993). The accumulation of wild-type p53 protein
can be explained by means of the formation of a complex with a
cellular (ex: mdm2) or viral (ex: HBx) protein. We have shown
that the tumours of all the patients with anti-p53 serum antibodies
exhibited microveinule invasion associated with cellular accumu-
lation of the p53 protein. This data raises the hypothesis that
tumours preferentially elicit an immune response against p53
when a vascular invasion is observed. This suggests that the asso-
ciation of p53 accumulation with presentation of the antigen to the
bloodstream seems to be required to induce a humoral response.
Presence of anti-p53 serum antibodies is regarded as a bad prog-
nostic factor in breast and head and neck cancer, or as an increased
risk for relapse but not death in ovarian and colon cancer
(Schlichtholz et al, 1992; Houbiers et al, 1995; Angelopoulou et al,
1996; Bourhis et al, 1996; Coomber et al, 1996). As previously
mentioned, eight patients of our series operated for HCC had anti-
p53 serum antibodies, and at least one factor of bad prognosis as
defined by the experience of different groups (Akashi et al, 1991;
Yamashita et al, 1991; Bismuth et al, 1993; Ganne-Cari￿ et al,
1996). However, they all had a survival rate without recurrence
significantly higher than that of the 24 patients with vascular inva-
sion but without circulating anti-p53 antibodies (P = 0.05, log-
rank analysis). A similar observation has been reported in
pancreatic tumours of advanced stage (Gansauge et al, 1996).
In conclusion, we observed a low incidence of circulating anti-
p53 antibodies in a population of 130 European patients followed
for proven HCC (9 out of 130, 7%). The humoral response did not
seem to correlate with the clinicopathological features of the
disease. However, the majority of patients who had anti-p53 serum
antibodies exhibited cellular accumulation of p53 protein associ-
ated with microvascular invasion in their tumour compared with
the group of seronegative patients. In most of them (five out of
six), no mutation of the p53 gene was detected. Presence of anti-
p53 serum antibodies does not seem to be associated here with a
poor prognosis. Further follow-up of these patients and analysis of
a greater number of cases will probably lead us to consider
whether anti-p53 serum antibodies constitute a marker of relative
￿good prognosis￿ in a subgroup of patients exhibiting one or
several markers traditionally thought to be of bad prognosis. This
test could be add to the other tests such as serum AFP levels and
radiographic scanning.
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